Die US-Arzneibehörde rechnet mit keiner Wirksamkeit beim Anti-Corona-Präparat Evusheld. | Heute.at

Die US-Arzneibehörde rechnet mit keiner Wirksamkeit beim Anti-Corona-Präparat Evusheld.

JONATHAN NACKSTRAND / AFP / picturedesk.com

Download von www.picturedesk.com am 23.02.2022 (10:39). A photo taken on February 8, 2022 shows a box of Evusheld, a drug for antibody therapy developed by pharmaceutical company AstraZeneca for the prevention of COVID-19 in immunocompromised patients at the AstraZeneca facility for biological medicines in Södertälje, south of Stockholm, Sweden. - AstraZenecas new facility in Sweden located in Södertälje was inaugurated last December and is dedicated to the production of next generation biological drugs such as Evusheld, a Covid-19 preventative monoclonal antibody treatment for immunocompromised people. (Photo by Jonathan NACKSTRAND / AFP) - 20220208_PD24864 - Rechteinfo: Rights Managed (RM) Nur fÃ¼r redaktionelle Nutzung! Werbliche Nutzung erfordert Freigabe: bitte schicken Sie uns eine Anfrage.